1998
DOI: 10.1016/s0168-3659(97)00256-3
|View full text |Cite
|
Sign up to set email alerts
|

Cross-linked high amylose starch for controlled release of drugs: recent advances

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
67
0

Year Published

2000
2000
2024
2024

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 111 publications
(67 citation statements)
references
References 8 publications
0
67
0
Order By: Relevance
“…More recently it was discovered that cross-linked starches possess unique features as an excipient for the manufacture of the controlled-release solid oral dosage form of drugs. 13,14 Chitosan has also been assessed for its potentiality in the development of controlled-release systems and for its propensity for targeting drugs to specific sites. 15,16 Numerous control or sustained delivery systems with chitosan have been described in the literature.…”
Section: Introductionmentioning
confidence: 99%
“…More recently it was discovered that cross-linked starches possess unique features as an excipient for the manufacture of the controlled-release solid oral dosage form of drugs. 13,14 Chitosan has also been assessed for its potentiality in the development of controlled-release systems and for its propensity for targeting drugs to specific sites. 15,16 Numerous control or sustained delivery systems with chitosan have been described in the literature.…”
Section: Introductionmentioning
confidence: 99%
“…Cross-linked high amylose starch (CLHAS) was introduced in the early 1990s as a tablet excipient for drug controlled release with the brand name Contramid Õ (Lenaerts et al, 1991(Lenaerts et al, , 1998Dumoulin et al, 1998). CLHAS is generally derived from the cross-linking of high amylose starch (70% amylose, 30% amylopectin) with epichlorohydrin or phosphate (Rahmouni et al, 2001).…”
Section: Cross-linked Starchmentioning
confidence: 99%
“…Compared to other excipients, CLHAS is more suitable for hydrophilic matrices preparation. The water uptake rate, drug release rate and equilibrium swelling are elevated with increasing crosslinking degree (cld), which is ascribed to the unique characteristics of CLHAS tablets, such as erosion resistance and swelling restriction (Lenaerts et al, 1998).…”
Section: Cross-linked Starchmentioning
confidence: 99%
See 2 more Smart Citations